Adjunctive Gypenosides for Acute Optic Neuritis

Summary

This pilot randomized, double-blind, placebo-controlled trial evaluated whether short-course adjunctive gypenosides, added to standard corticosteroid treatment, may preserve retinal structural outcomes in adults with acute optic neuritis.

Timeline

Start

2017-02-04

Primary completion

2018-07-30

Completion

2018-07-30

Outcome

Missed primary endpoint

Stopped (Enrollment): “Slow recruitment and an unexpectedly high proportion of AQP4-IgG-positive optic neuritis on masked feasibility review limited feasibility. No interim efficacy analysis was performed.”

paper did not meet the pRNFL primary endpoint. PMID 42398278 ↗

Publications

• Lu Y, Zhao M, Luo W, Du Y. Adjunctive gypenosides for acute optic neuritis: A prematurely terminated randomized, double-blind, placebo-controlled pilot trial in a cohort with frequent AQP4-IgG positivity. Mult Scler Relat Disord. 2026 Jun 27;113:107346. doi: 10.1016/j.msard.2026.107346. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gypenosides	Unknown	60 mg	Oral

Indications